Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Publisher: La Merie Publishing
Pages: 78
Format: PDF
Product Line:
Target Pipeline
Product Line:
Competitor Analysis
Product Code: LMCA0157
Release Date: July of 2018

500.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

This Competitive Intelligence report analyzes the competitive field of CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators as of July 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage. The mainly selective, but also bispecific new molecular entities activate the immune checkpoints, including

  • CD40 (TNFSFR5)
  • GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
  • OX40 (CD134; TNFSFR4)
  • 4-1BB (CD137; TNFSFR9)
  • CD27 (TNFSFR7)
  • ICOS (Inducible Co-Stimulator)

At least 32 new molecular entities (NMEs), mostly selective antibodies, activating immune checkpoints are in clinical development as monotherapy or in combination with other checkpoint modulators. At least 16 further NMEs are undergoing IND-enabling studies and numerous preclinical approaches are under evaluation.

The report includes a compilation of currently active projects in research and development of mostly recombinant antibodies activating immune checkpoints CD40, GITR, OX40, 4-1BB, CD27, ICOS & others. In addition, the report lists company-specific R&D pipelines of activators of immune checkpoints. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018

Table of Contents:

1)        CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators
1a) CD40 Agonists
1b) GITR Agonists
1c) OX40 Agonists
1d) 4-1BB (CD137) Agonists
1e) CD27 Agonists1f) ICOS Agonists
1g) Other Immune Checkpoint Activators

2)        Corporate Immune Checkpoint Activator R&D Pipelines



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top